This page is updated frequently with new Prostate Cancer-related patent applications.
|Galectin-3 as a marker for prostate cancer|
Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (psa), as a marker for the presence or absence of and/or activity of prostate cancer.. .
Wayne State University
|Histone demethylase inhibitors|
The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.
|Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies|
Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer.
Tokai Pharmaceuticals, Inc.
|Cabazitaxel and its use for treating metastatic prostate cancers|
For its use for the treatment of castration resistant or hormone-refractory metastatic prostate cancer in patients not at risk of developing gastrointestinal disorders chosen from the group consisting of: gastrointestinal bleeding and perforation, gastritis, enterocolitis, neutropenic enterocolitis, colitis, intestinal obstruction, and ileus.. .
|System and diagnosis and treatment|
This invention relates the use of cortisol blockers (glucocorticoid receptor [gr] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.. .
Pop Test Oncology Limited Liability Company
|Method for the diagnosis, prognosis and treatment of prostate cancer metastasis|
The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-maf gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which, comprise determining the c-maf expression level.
|Androgen receptor down-regulating agents and uses thereof|
The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (ar), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional ar..
University Of Maryland, Baltimore
Provided are stat3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer..
Board Of Regents, The University Of Texas System
|Method of treating patients with a mucinous glycoprotein (muc-1) vaccine|
The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a muc-1-based formulation. The formulation may be a muc-1 based liposomal vaccine formulation..
|Methods for diagnosing cancer based on small nucleolar rna hbii-52|
Provided are compositions and methods for detecting in a sample the presence or absence, and/or the amount, of a small nucleolar rna (snorna) hbii-52, also known as snord115. The compositions and methods are useful in diagnosis, prognosis, therapy recommendations, therapy, and monitoring of therapy for individuals who have a disorder that is positively correlated with elevated hbii-52, such as cancer, and particularly for prostate cancer.
Health Research, Inc.
Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer..
Superlab Far East Limited
Zinc n-acetyl taurinate for the treatment of prostate cancer
The present invention relates to zn n-acetyl taurinate of formula (i): [ch3—co—nh—ch2—ch2—so3]−2zn2+ for the use thereof for treating prostate cancer. .
Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.. .
The Johns Hopkins University
Compositions and methods for treatment and detection of cancers
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to ssea-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics.
Androgen receptor modulators and methods for their use
Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1, r2, r3, r4, r6, y1 and y2 are as defined herein, and wherein at least one of r3 or r4 is a straight-chain c1-c6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided..
Methods for screening, predicting and monitoring prostate cancer
Biomarkers are identified by analyzing gene expression data using support vector machines (svm) to rank genes according to their ability to separate prostate cancer from normal tissue. Expression products of identified genes are detected in patient samples, including prostate tissue, serum, semen and urine, to screen, predict and monitor prostate cancer..
Health Discovery Corporation
Mirna fingerprint in the diagnosis of prostate cancer
Micrornas (mirna) are a recently discovered class of small non-coding rnas (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer.
Comprehensive Biomarker Center Gmbh
Kits for antiandrogen therapy monitoring
The present invention provides methods of evaluating the effectiveness of an antiandrogen therapy in a human by comparing the pre- and post antiandrogen treatment levels of an androgen modulated diagnostic marker and a prostate-specific, androgen independent, diagnostic marker in the human. Methods utilizing these markers are also provided that are useful for identifying antiandrogen compounds capable of killing prostate cancer cells, and identifying a human suspected of responding more, or less, favorably to treatment with an antiandrogen compound and monitoring the treatment thereof.
Method for the detection and quantitation of biomarkers
The invention provides a method for detecting the presence or absence of a biomarker in a biological sample at a very low concentration comprising the steps of (a) contacting the biological sample with a capture binding sequence immobilized on a surface, (b) providing a conjugate comprising a detection binding sequence-glucose oxidase, (c) contacting the surface with the detection binding sequence-glucose oxidase conjugate, (d) separating any unbound detection binding sequence-glucose oxidase conjugate from the surface, (e) incubating the resulting surface with a glucose solution and a mixture comprising gold nanoparticles and a gold salt, wherein the gold nanoparticles have an initial particle size of about 5 nm, and (f) observing any change in color of the mixture. The invention also provides a method for diagnosing the presence of a prostate cancer biomarker in a subject and a kit for detecting or quantifying a biomarker in a biological sample..
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
Biomarkers in cancer, methods, and systems related thereto
This disclosure relates biomarkers of cancer, e.g. prostate cancer.
Nucleic acid biomarkers for prostate cancer
This invention relates to microrna biomarkers useful in the diagnosis and prognosis of prostate cancer. The biomarkers are also useful for the monitoring and/or treatment of prostate cancer..
Institute Of Cancer Research: Royal Cancer Hospital
Pyrazole linked benzimidazole conjugates and a process for preparation thereof
Pyrazole linked benzimidazole conjugates and a method for synthesis of one or more compounds having a pyrazole linked benzimidazole conjugate, particularly pyrazole linked benzimidazole conjugates that are useful as potential antitumor agents against human cancer cell lines, such as leukemia, non-small cell lung cancer, colon cancer, cns cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer. The process comprises the step of oxidative cyclization of o-phenylenediamines and 3-phenyl-1h-pyrazole-5-carbaldehydes with sodium metabisulphite in ethanol/methanol solvent system at a desired temperature for a period of time to obtain the pyrazole linked benzimidazole conjugate..
Council Of Scientific & Industrial Reseach
Bufalin liposome, preparation method therefor and application thereof
The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (peg)-derived compound.
The Fourth Military Medical University
Selective androgen receptor modulators
This invention provides compounds of formula i, pharmaceutical compositions comprising a compound of formula i and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.. .
Radius Health, Inc.
Novel compositions and methods for treating prostate cancer
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. In some embodiments, the solid matrix comprises a polymer.
Tokai Pharmaceuticals, Inc.
Near infrared photonic prostatoscopy analyzer
A rectal near infrared (nir) scanning polarization imaging system uses nir photonic prostatoscopy analyzer (nirppa) for prostate cancer detection using light. The nirppa consists of a portable rectal nir scanning polarization imaging unit and an optical fiber-based rectal probe capable of recording sets of 2d images of a prostate through rectum at different wavelengths and depths and obtaining a three dimensional (3d) image of the prostate and 3d locations of abnormal tissue inside the prostate.
Method for indicating a presence or non-presence of aggressive prostate cancer
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer.
Prostate cancer testing and diagnosis method
A molecular assay of prostate cancer testing and diagnosis method is provided. The tests of the present invention include a broad spectrum analysis of testing molecular values for prostate cancer management.
Methods for diagnosing and treating prostate cancer
The invention is directed to a method of inhibiting prostate cancer cell proliferation using a substance that inhibits the activity of a soluble adenylyl cyclase (sac) protein. The invention also is directed to methods of diagnosing and prognosticating prostate cancer in a subject by evaluating sac gene or protein expression in the subject..
Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
The invention provides methods and products to detect the presence of unidentified high grade prostate tumors in a subject with a gleason score 7 prostate tumor. The method comprises obtaining a biological sample from a subject in need thereof, measuring a profile of metabolites in the biological sample, wherein the metabolites are differentially expressed in gleason score 6 versus gleason score 8 prostate tumors, and classifying the profile of the metabolites to assign a grade to the sample based on the profile of the metabolites..
The Brigham And Women's Hospital, Inc.
Diagnostic markers of indolent prostate cancer
A 3-gene prognostic panel has been identified that together accurately predicted the outcome of low gleason score prostate tumors as either truly indolent or at a high risk of becoming aggressive. The 3-gene prognostic panel was validated on independent cohorts confirmed its independent prognostic value, as well as its ability to improve prognosis with currently used clinical nomograms.
The Trustees Of Columbia University In The City Of New York
Prostate cancer prognostic compositions and kits
Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of pca3 and of a prostate-specific marker expression in a urine sample and correlating the value of the pca3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject.
Stichting Katholieke Universiteit, The University Medical Centre Nijmegen
Prostate cancer vaccine
Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer.
Wisconsin Alumni Research Foundation
Genomic classifiers for non-invasive identification of high grade prostate cancer with metastatic potential
The present invention relates to the field of biomarkers. More specifically, the present invention provides methods and compositions useful for diagnosing and/or prognosing prostate cancer.
The Johns Hopkins University
Conjugates for treating diseases caused by psma expressing cells
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by psma expressing cells, such as prostate cancer cells, using compounds capable of targeting psma expressing cells..
Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
Provided are methods of inhibiting cyp17 in a mammal, such as a human, that include administering an effective amount of at least one cyp17 inhibitor, such as vn/124-1, vn/125-1, vn/85-1, vn/87-1 and/or vn/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (ar) protein expression and methods of antagonizing ar in a mammal that include administering to the mammal an effective amount of at least one active ingredient selected from vn/124-1, vn/125-1, vn/85-1, vn/87-1 and vn/108-1.
University Of Maryland, Baltimore
Methylation biomarkers for prostate cancer
Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.. .
Organic compositions to treat beta-catenin-related diseases
The present disclosure relates to rnai agents useful in methods of treating beta-catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a rnai agent to beta-catenin.. .
Histone demethylase inhibitors
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds.
Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
Mitochondrial dna deletions useful for the detection of cancers and sun exposure are provided. In particular, methods and kits for detecting mitochondrial dna deletions for the early detection, diagnosis and progression of prostate cancer, sun exposure and non-melonoma skin cancer are provided..
Prognostic individuals with prostate cancer
The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery.
Fosfestrol for use in curative or palliative treatment of prostate cancer
The present invention relates to the use of fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality.
Biomarkers for aggressive prostate cancer
The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing aggressive prostate cancer.
The Johns Hopkins University
Drug coated balloon catheters for nonvascular strictures
Embodiments of the present invention provide a method for treatment of nonvascular body lumen strictures such as benign prostatic hyperplasia (bph), urethral strictures, ureteral strictures, prostate cancer, esophageal strictures, sinus strictures, biliary tract strictures, asthma and chronic obstructive pulmonary disease (copd). The method involves delivering, preferably via drug coated balloon catheters, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and one or more additives..
Method for treating prostate cancer
The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of cdk8 and cdk19. In some embodiments the inhibitor inhibits cdk19.
University Of South Carolina
Multimodal microscopy for automated histologic analysis of prostate cancer
The present disclosure relates to methods of diagnosing prostate cancer using different imaging methods. For example, it is shown herein that combining a fourier transform infrared (ft-ir) spectroscopic image with an optical image (such as a hematoxylin and eosin image) allows for automated detection of prostate cancer with high accuracy..
The Board Of Trustees Of The University Of Illinois
Selective androgen receptor modulators
This invention provides compounds of formula (ii), or (iia) and or salts thereof, pharmaceutical compositions comprising a compound of formula (ii), or (iia) and a pharmaceutically acceptable excipient, processes for making compounds of formula (ii), or (iia) and intermediates useful in the preparation of same; and methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type ii diabetes related disorders or diseases, anemia, depression, and renal disease) using compounds of formula (i), (ii) or (iia).. .
Radius Health, Inc.
Compositions and methods for the treatment of disease associated with trp-p8 expression
Provided are small-molecule trp-p8 modulators, including trp-p8 agonists and trp-p8 antagonists, and compositions comprising small-molecule trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule tip-p8 modulators and methods for decreasing viability and/or inhibiting growth of trp-p8 expressing cells, methods for activating trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with tip-p8 expression.. .
Androgen receptor variants and methods for making and using
The present invention encompasses the recognition that an f876l mutation of the androgen receptor (ar) gene confers resistance to the antiandrogens enzalutamide (mdv3100) and arn-509 and is associated with incidence and/or risk of castration resistant prostate cancer (crpc). The present invention also provides other ar polypeptide sequences associated with increased incidence and/or risk of crpc.
Memorial Sloan-kettering Cancer Center
Prostatitis-associated antigens and methods of use thereof
The present disclosure provides prostatitis-associated antigens, and compositions comprising the antigens. The present disclosure provides diagnostic methods, generally involving assaying the level of an immune response specific for a prostatitis-associated antigen in an individual.
The Regents Of The University Of California
Gene-gene model for estimating cancer susceptibility, risk of multiple tumor sites, and the aggressiveness of prostate cancer
The present disclosure provides methods for estimating cancer susceptibility, risk of developing multiple tumor sites, and the aggressiveness of prostate cancer. Disclosed are interactions among three polymorphisms: the acid phosphatase locus-1 (acp1) 228c>t (rs11553742) and 413a>g (q106r, rs79716074) single nucleotide polymorphisms (snps), and a snp for the astrocyte elevated gene-1 (aeg1) (rs2438211).
Genetic Research Institute Of The Desert
T cell receptor-like antibodies specific for a wti peptide presented by hla-a2
The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
Eureka Therapeutics, Inc.
Method for producing sulfonyl amidine compound
Provided are a method for producing a sulfonyl amidine compound, which has an excellent gonadotropin releasing hormone receptor antagonism and is useful as a therapeutic agent for gonadotropin-dependent diseases (for example, prostate cancer, breast cancer, endometriosis, uterine fibroid, prostatic hyperplasia, or the like) or a salt thereof, and a synthesis intermediate useful in the production method. The production method of the present invention controls formation of a by-product which is hardly removed unless column purification is conducted and racemization of a target compound, thereby obtaining the target compound with a high purity, and therefore, the production method is suitable for industrial production..
Astellas Pharma Inc.
Tumor plus adjacent benign signature (tabs) for quantitative histomorphometry
Methods, apparatus, and other embodiments associated with predicting prostate cancer (cap) progression using tumor cell morphology features and benign region graph features are described. One example apparatus includes a set of logics that acquires an image of a region of tissue, detects and segments cells in the image, extracts a set of morphological features from cells in a first region in the image, constructs a graph of a localized cellular network in a second region of the image, extracts a set of graph features from the graph, generates a set of tumor plus adjacent features signature (tabs) features from the sets of graph features and the set of morphological features, and calculates the probability that the image is a progressor or non-progressor based, at least in part, on the set of tabs features.
Case Western Reserve University
Group-sparse nonnegative supervised canonical correlation analysis (gncca)
Methods, apparatus, application specific integrated circuits (asic)s and other embodiments associated with analyzing a cancerous prostate using group-sparse non-negative canonical correlation analysis (gncca) with a variable importance in the projections (vip) score are described. One example apparatus includes a set of logics that acquires a set of features from a plurality of feature views of a region of tissue demonstrating cancerous pathology, produces a ranked set of discriminative features using gncca with the vip score, optimizes computation of the gncca using a vector-block coordinate descent (bcd) approach, and provides a prostate cancer (cap) grade or a biochemical recurrence (bcr) score based on the set of discriminative features.
Case Western Reserve University
Methods and compositions for prostate cancer metastasis
Provided are methods and compositions for determining an increased likelihood of prostate cancer cells in a subject to metastasize.. .
Florida Agricultural And Mechanical University (famu)
Methods and compositions for determining resistance to androgen receptor therapy
Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides.
Aragon Pharmaceuticals, Inc.
Gene expression profiling for the diagnosis of prostate cancer
Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of rna biomarkers in a biological sample obtained from the subject, for example, using ngs technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the rna biomarkers that are above or below the predetermined threshold levels are indicative of the presence of prostate cancer in the subject.
Caldera Health Ltd.
Composition and diagnosis and immunotherapy of prostate cancer
A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant akap-4 tumor-associated antigen loaded antigen presenting cell that generates an akap-4 specific cytotoxic t lymphocyte specific for one or more prostate cancer cells.. .
Texas Tech University System
Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
The present invention concerns means and methods for cancer diagnosis and, in particular, diagnosis of prostate cancer. Specifically, it relates to a method for diagnosing whether a subject is at risk for recunent prostate carcinoma after prostatectomy comprising determining the amount of at least one metabolite selected from table 2 in a test sample of a subject after prostatectomy, and comparing the determined amount to a reference, whereby it is diagnosed whether the subject is at risk for recurrent prostate carcinoma after prostatectomy.
Metanomics Health Gmbh
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity. Such conditions include, but not limited to, arthritis, alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, t-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, t-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or type i diabetes, complications from diabetes, rheumatoid arthritis, asthma, crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis.
Identifying taxane sensitivity in prostate cancer patients
The invention relates to detection and/or treatment of a subset of prostate cancer patients who may benefit from taxane treatment. The method comprises testing whether an androgen receptor (ar) splice variant is present in a test sample obtained from the patient, wherein the androgen receptor variant can be arv5,6,7 or arv7, or a combination thereof..
University Of Washington
Compositions and methods for treatment of prostate and other cancers
Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or rnai nucleotide inhibitor with sequence specificity for hsp27 mrna, for example human hsp27 mrna, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount.
The University Of British Columbia
Prostate cancer markers and uses thereof
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to lipids as diagnostic markers for prostate cancer..
Oslo Universitetssykehus Hf
System and detecting of alpha-methylacyl-coa racemase (amacr) and prostate cancer
A detection system for determining alpha-methylacyl-coa (amacr) levels in a bodily sample includes at least one reaction solution for generating h2o2 upon combination with amacr in the bodily sample and a biosensor for determining a level of generated h2o2. The reaction solution includes a (2r)-2-methylacyl-coa epimer that can be chirally inverted by amacr to a (2s)-2-methylacyl-coa epimer and an enzyme that carries out beta oxidation with the (2s)-2-methylacyl-coa epimer to generate hydrogen peroxide (h2o2)..
Case Western Reserve University
Imidazoline derivatives, preparation methods thereof, and their applications in medicine
Preparation methods thereof, pharmaceutical compositions comprising such derivatives, and applications of such derivatives in preparing androgen receptor antagonists and medicaments for treating diseases such as prostate cancer are described.. .
Combination treatment with vegf-c antagonists
The invention relates to a method and kit for treating cancer in a human subject, the method comprising administering to the subject in combination therapeutically effective amounts of a vegf-c antagonist and an anti-neoplastic composition, and the kit comprising a vegf-c antagonist for administering to the subject in combination with an anti-neoplastic composition. The invention further relates to methods for: increasing the duration of survival of, increasing the progression-free survival of, increasing the duration of response of, or treating, a subject or a group of human subjects susceptible to or diagnosed as having a cancer; or treating a human subject or a group of human subjects having metastatic colorectal cancer, prostate cancer, pancreatic cancer or glioblastoma, the methods comprising administering to the subject or subjects in the group in combination effective amounts of a vegf-c antagonist and an anti-neoplastic composition..
Vegenics Pty Limited
Prostate Cancer topics:
Pharmaceutically Acceptable Salt
Hormone Refractory Prostate Cancer
Follow us on Twitter
This listing is a sample listing of patent applications related to Prostate Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Prostate Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.